September 9, 2026
Navion Neurosciences Closes $10.8 Million Seed Financing to Advance Precision Sodium-Channel Medicines for Epilepsy and Neuropathic Pain
Navion announces a $10.8 million seed financing first closing to advance genetic epilepsy and chronic neuropathic pain programs and expand its AI-enabled NaViGATion™ discovery platform.
Read more →